Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The companies said the U.S. Food and Drug Administration cleared their Alzheimer’s blood test, a move that could support broader screening as the market seeks less invasive options than current diagnostic pathways.
THE APEX TIMES
THE APEX TIMES
A market-focused note says the billionaire investor increased his Eli Lilly position in the second quarter and that the bet has moved in his favor, highlighting how quickly large healthcare trades can reprice.
THE APEX TIMES
Lilly’s market optimism is again centered on Mounjaro and Zepbound widening its lead in a booming obesity-and-diabetes class, while expectations for further growth options build around its next-generation drug work.
THE APEX TIMES
Veeva Systems said Eli Lilly is committing to deploy Veeva Vault CRM globally, even as the company announced that President and Chief Customer Officer Thomas D. Schwenger will leave in October 2026. Analysts will likely watch whether the leadership transition affects how aggressively Veeva pushes new CRM capabilities to big pharma clients.
THE APEX TIMES
Lilly’s stock climbed after a report tied to new UK approval for its next GLP-1 asset and continued expansion of its obesity and diabetes franchise. Investors also reacted to signs of broader pipeline progress and an improved full-year outlook.
THE APEX TIMES
Bristol-Myers Squibb said Aug. 10 it expects to spend about $2.3 billion on a new manufacturing plant in Houston. The same market report highlighted Eli Lilly’s progress in the United Kingdom, setting up a contrast between new U.S. capacity buildout and overseas momentum.
THE APEX TIMES
Market observers say consensus expectations for Eli Lilly still assume slower growth than the company has been delivering, while also assuming profit margins rise from a level the firm only recently reached.
THE APEX TIMES
With shares recently trading around $1,280, investors are again asking whether Eli Lilly could be the next major U.S. company to split its stock to keep the price accessible.
THE APEX TIMES
Across biopharma, shareholder activism and platform competition are colliding. A new push by Kaos Capital targets Capricor’s board and strategy, while Eli Lilly outlines continued focus on vaccine development. In parallel, Bristol Myers is advancing work described as an AI-powered discovery engine.
